Equillium, Inc.

EQ

US29446K1060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.8423 ^USD	+10.68%		+23.89%	+16.50%

Jul. 01	Equillium, Inc.(NasdaqCM:EQ) added to Russell 3000E Index	CI
Jul. 01	Equillium, Inc.(NasdaqCM:EQ) added to Russell Microcap Index	CI

Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.

May 09, 2024 at 04:06 pm EDT

From January 1, 2024 to May 9, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 298,385 shares, representing 0.86% for $0.25 million under the buyback announced on August 2, 2023.

Latest news about Equillium, Inc.

Equillium, Inc.(NasdaqCM:EQ) added to Russell 3000E Index	Jun. 30	CI
Equillium, Inc.(NasdaqCM:EQ) added to Russell Microcap Index	Jun. 30	CI
Equillium, Inc.(NasdaqCM:EQ) added to Russell Microcap Growth Index	Jun. 30	CI
Equillium, Inc.(NasdaqCM:EQ) added to Russell 3000E Growth Index	Jun. 30	CI
Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101	Jun. 04	CI
Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	May. 14	CI
Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M	May. 09	MT
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.	May. 09	CI
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	Apr. 02	MT
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	Apr. 01	CI
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26	DJ
Equillium Swings to Q4 Loss As Revenue Falls	Mar. 25	MT
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.	Mar. 25	CI
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	Mar. 25	MT
HC Wainwright Adjusts Price Target on Equillium to $4 From $4.50, Keeps Buy Rating	Dec. 26	MT
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21	CI
HC Wainwright Adjusts Equillium's Price Target to $4.50 From $5.50, Maintains Buy Rating	Nov. 13	MT
Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology	Nov. 13	CI
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.	Nov. 08	CI
Equillium, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (EQ) EQUILLIUM Reports Q3 Revenue $8.9M	Nov. 08	MT
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology	Nov. 06	CI

Chart Equillium, Inc.

Duration

Period

More charts

Company Profile

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Companyâs pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Companyâs EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.

Sector

Pharmaceuticals

Calendar

2024-07-15 - Jones Healthcare Seaside Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Equillium, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8423 USD

Average target price

6.75 USD

Spread / Average Target

+701.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EQUILLIUM, INC.	+16.50%	29.7M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals

Equillium, Inc.

Equities

EQ

US29446K1060

Pharmaceuticals

Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.

EPS Revisions